Health News Releases

14:05

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcomin

December 12, 10:00

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on t

December 11, 17:50

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with th

December 11, 16:35

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating pa

December 11, 15:40

Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers

Baszucki Group today announced an expanded commitment to the landmark Cleveland Clinic Brain Study (https://my.clevelandclinic.org/departments/neurological/research-innovations/brain-study). Launched

December 10, 15:35

SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

SoluPet, the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announced a strategic partnership with CHC, one of Asia’s largest p

December 10, 14:10

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innova

December 09, 16:40

IBMI SNQ and ICHOM Forms Strategic Partnership in Asia, Advancing Patient-centered Healthcare in the Region

The Symbol of National Quality (SNQ), initiated by Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI), has partnered with the International Consortium for Health Outcomes Measurement (I

December 09, 15:20

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 i

December 09, 15:00

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results o

December 08, 15:12

Galderma Welcomes Increased Equity Investment From L’Oréal

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake

December 05, 17:15

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance o

December 05, 15:40

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU

December 05, 14:15

Parse Biosciences Launches Evercode Whole Blood Fixation

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixati

December 05, 11:20

University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health

Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in

December 05, 11:00

Famenity's Brain Factor-7® Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health

Famenity Co., Ltd. (https://famenity.com/home-en/), a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®)

December 04, 15:09

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive o

November 27, 16:00

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

BeOne Medicines Ltd (https://beonemedicines.com/). (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and

November 26, 16:20

With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (3

November 25, 09:40

Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis

Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, c

November 23, 11:30

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54361159&newsitemid=20251120303213&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5

November 21, 14:20

Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement

Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round wa

November 21, 14:07

K2 MEDITECH Sets a New Benchmark in the Global Skin Booster Market

Built on innovative skin-regeneration technology, K2 MEDITECH is rapidly gaining attention in the global beauty and medical aesthetics industries. As a specialized manufacturer of skin boosters, th

November 20, 15:10

Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraff

November 20, 15:00

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial e

News by Region

News by Industry